[A23-114] Baricitinib (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V

Last updated 15.02.2024

Project no.:
A23-114

Commission:
Commission awarded on 14.12.2023 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Children's and adolescents' health

Indication:

Children and adolescents with active enthesitis-related psoriatic arthritis who have had an inadequate response or intolerance to one or more conventional synthetic or biologic disease-modifying antirheumatic drugs (DMARDs)

Result of dossier assessment:
  • Children 2 to 5 years of age: added benefit not proven
  • Children and adolescents 6 years of age and older: added benefit not proven
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

DOI:

https://dx.doi.org/10.60584/A23-114_en

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form